🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the effort against increasingly resistant strains of the pathogen, according to health experts.

A Global Health Concern

Gonorrhoea infections are escalating worldwide, with data suggesting over 82 million new cases each year. Particularly high rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an important and timely step in the face of rising global incidence, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Public health authorities are particularly alarmed about the surge in drug-resistant strains. The WHO has designated it as a "priority pathogen". Ongoing monitoring found that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

One new antibiotic, also known as a brand name, was authorized by the US FDA in mid-December for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This medication, which is employed against urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The charitable organization GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This authorization represents a significant shift in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Clinical Trial Results and Worldwide Availability

Based on findings released by a prominent scientific publication, the new drug successfully treated more than 90% of cases of the STI. This puts it on an equal footing with the existing first-line therapy, which combines two antibiotics. The research included nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have shared positive views. Access to a single-dose, oral treatment such as this is described as a "game-changer" for public health efforts. This is deemed essential to reduce the burden of the infection for individuals and to stop the proliferation of highly drug-resistant gonorrhoea globally.